CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 20 enrolled
Drug / intervention
regadenosondrug
Likely dose
regadenoson 0.4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00871260
NCT00871260Phase 4Completed
CompareCT.gov

Stress Testing and Cardiac Magnetic Resonance

University of Chicago·interventional·Posted Mar 30, 2009·Updated Jul 12, 2021

In Brief

A Phase 4 clinical trial evaluating regadenoson for Coronary Disease. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The purpose of this study is to better define the role of a comprehensive stress MRI (which includes myocardial perfusion imaging, optimized coronary imaging, and myocardial scar imaging) in medical practice and in patient health management. Information gathered from the healthy volunteers that participate in this study will be compared to information from the coronary artery disease patients in this study in order to help further our understanding.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Disease
CountriesUnited States
CollaboratorsAstellas Pharma Inc

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 30, 2009
Enrollment StartApr 1, 2009
Primary CompletionJun 4, 2014
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 17.3 years ago

Interventions

regadenosondrug

Subjects in open label group will be given a single dose of regadenoson (0.4 mg, i.e. 5 ml i.v. bolus) as contrast.